Jill Feldman interviews Dr. Eric Singhi about Lung Cancer Comprehensive biomarker testing to guide lung cancer treatment
Lung Cancer and Comprehensive Biomarker Testing
Getting the right tests might help find your cancer's weakness.
April 21 at
4:00 PM PT / 7:00 PM ET
7:00 PM PT / 10:00 PM ET
If you or someone you love has been diagnosed with non-small cell lung cancer (NSCLC), you’ve likely heard the phrase ‘biomarker testing’ and the need to wait for results. This wait can feel unbearable, but the science is clear: knowing what is driving your specific cancer before you start treatment can change everything about the care you receive.
This program will explain why comprehensive biomarker testing is the foundation of the right treatment plan.
You will learn:
What biomarker testing is and why it’s not inherited genetic testing.
Why waiting for test results leads to better outcomes.
Tissue vs. liquid biopsy: when and why both are needed.
Common NSCLC biomarkers (EGFR, ALK, KRAS, ROS1, MET, PD-L1) and their treatment meaning.
How targeted therapy, immunotherapy, and chemotherapy differ, and when to use each.
What cancer progression means and why retesting is essential.
How to advocate for yourself and be an active partner in your care.
Program Sponsors
Thank you to our sponsors for their support of our independent patient education program. The Patient Story retains full editorial control over all content.
Discover How Getting the Right Tests Can Change Everything.
This webinar has been completed!
This webinar has not yet been completed.
Lung Cancer and Comprehensive Biomarker Testing
Hosted by The Patient Story Team | 53m
The science is clear: knowing what is driving your specific cancer before you start treatment can change everything about the care you receive. This program will explain why comprehensive biomarker testing is the foundation of the right treatment plan.